Suppr超能文献

高渗高渗胶体溶液可改善儿童心脏直视手术后的心脏功能。

Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.

作者信息

Schroth Michael, Plank Christian, Meissner Udo, Eberle Klaus-Peter, Weyand Michael, Cesnjevar Robert, Dötsch Jörg, Rascher Wolfgang

机构信息

Kinder- und Jugendklinik, Department of Pediatrics, Pediatric Intensive Care Unit, Friedrich-Alexander-University Erlangen-Nuremberg, Loschgestrasse 15, D-91054 Erlangen, Germany.

出版信息

Pediatrics. 2006 Jul;118(1):e76-84. doi: 10.1542/peds.2005-2795. Epub 2006 Jun 2.

Abstract

OBJECTIVES

Hypertonic-hyperoncotic solutions are used for the improvement of micro- and macrocirculation in various types of shock. In pediatric intensive care medicine, controlled, randomized studies with hypertonic-hyperoncotic solutions are lacking. Hypertonic-hyperoncotic solutions may improve cardiac function in children. The primary objective of this controlled, randomized, blinded study was to evaluate the hemodynamic effects and safety of hypertonic-hyperoncotic solution infusions in children shortly after open-heart surgery for congenital cardiac disease. The secondary objective was to determine whether the administration of hypertonic-hyperoncotic solutions could be a potential and effective therapeutic option for preventing a probable capillary leakage syndrome that frequently occurs in children after open-heart surgery.

METHODS

The children were randomly assigned to 2 groups of 25. The hypertonic-hyperoncotic solution group received Poly-(O-2)-hydroxyethyl-starch 60.0 g, with molecular weight of 200 kDa, Na+ 1232 mmol/L and osmolality of 2464 mOsmol/L (7.2% sodium chloride with 6% hydroxyethyl-starch 200 kDa). The isotonic saline solution group received isotonic saline solution (0.9% sodium chloride). Atrial and ventricular septal defects were corrected using a homograft patch. Monitoring consisted of an arterial, a central venous, and a thermodilution catheter (PULSIOCATH). Cardiac index, extravascular lung water index, stroke volume index, mean arterial blood pressure, and systemic vascular resistance index were measured (Pulse Contour Cardiac Output technique). Immediately after surgery, patients were loaded either with hypertonic-hyperoncotic solution or with isotonic saline solution (4 mL/kg). Blood samples (sodium concentration, osmolality, thrombocyte count, fibrinogen, and arterial blood gases) were drawn directly before; immediately after; 15 minutes after; and, 1, 4, 12, and 24 hours after the end of volume loading. Hemodynamic parameters were registered at the same time. The total amount of dobutamine required was documented, as well as the 24- and 48-hour fluid balances.

RESULTS

In the hypertonic-hyperoncotic solution group, cardiac index was 3.6 +/- 0.26 L/min per m2 before volume administration and increased to 5.96 +/- 0.27 after the administration of the study solution (64%). Fifteen and 60 minutes after administration, the cardiac index remained significantly elevated (5.55 +/- 0.29 L/min per m2 and 4.65 +/- 0.18 L/min per m2, respectively) and returned to preadministration values after 4 hours. In the isotonic saline solution group, the cardiac index did not change during the entire observation period (3.39 +/- 0.21 before and 3.65 +/- 0.23 L/min per m2 after isotonic saline solution). The systemic vascular resistance index decreased in the hypertonic-hyperoncotic solution group after administration from 1396 +/- 112 to 868 +/- 63 dyn/sec per cm(-5)/m2. The decrease of systemic vascular resistance index in the hypertonic-hyperoncotic solution group was transiently significant within 60 minutes after administration but stayed lower than before volume load (999 +/- 70 dyn/sec per cm-(5)/m2). In the isotonic saline solution group, we found no statistically relevant change in systemic vascular resistance index. Stroke volume index significantly increased after hypertonic-hyperoncotic solution infusion (53.9 +/- 3.0 mL/m2 directly after, 48.8 +/- 2.46 mL/m2 15 minutes after, and 41.4 +/- 2.2 mL/m2 60 minutes after) when compared with stroke volume index before administration (32.4 +/- 2.6 mL/m2). In the hypertonic-hyperoncotic solution group, an increase in mean arterial blood pressure remained transiently significant within 60 minutes after administration when compared with the isotonic saline solution group, in which the mean arterial blood pressure remained unchanged. Both central venous pressure and heart rate were unchanged during the whole time of observation in both groups. In the hypertonic-hyperoncotic solution group, extravascular lung water index decreased from 10.6 +/- 1.2 to 5.6 +/- 1.2 mL/kg and remained significantly decreased 15 minutes after (6.5 +/- 1.2 mL/kg) when compared with before volume administration. In the isotonic saline solution group, extravascular lung water index increased from 12.3 +/- 1.1 mL/kg to 18.1 +/- 1.7 mL/kg directly after administration and remained elevated for 60 minutes after volume loading (15.6 +/- 1.5 mL/kg). In all patients, no hypoxia (Pa(O2)<60 mm Hg) or hypercapnia (Pa(CO2) >60 mm Hg) was observed. Arterial blood gas analysis showed pH and base excess within physiologic range, and this did not change throughout the whole period of observation. After infusion of hypertonic-hyperoncotic solution, sodium concentration increased from 139.2 +/- 0.7 to 147.5 +/- 0.7 mmol/L. The maximum sodium concentration was 153 mmol/L, measured immediately after hypertonic-hyperoncotic solution in 1 patient. The total amount of fluid infused was similar in both groups. The postoperative need for infused dobutamine in the patients in the hypertonic-hyperoncotic solution group was decreased compared with the isotonic saline solution group (46.9 +/- 8.8 microg/kg vs 308.2 +/- 46.6 microg/kg). No patient presented with severe bleeding. Short- and long-term cardiac and neurologic outcome was not reduced and all patients left the hospital in a clinically sufficient state.

DISCUSSION

This study demonstrates a profound increase of cardiac index after the administration of hypertonic-hyperoncotic solution in children after uncomplicated open-heart surgery, suggesting a positive inotropic effect. The total amount of catecholamine was lower, assuming that hypertonic-hyperoncotic solution reduces the need for positive inotropic support. The observed positive cardiac effect of hypertonic-hyperoncotic solution may even be intensified by the decreased afterload (decreased systemic vascular resistance index). According to the Frank-Starling relation, an effective tool in the treatment of low cardiac output are an elevated preload while afterload is diminished. Therefore, we postulate that hypertonic-hyperoncotic solution may be helpful in preventing or attenuating low cardiac output failure in childhood. Capillary leakage syndrome also is a frequent problem after cardiopulmonary bypass. For quantification of edema formation, extravascular lung water index measurement is a useful tool. Using this approach, we provided evidence that the infusion of hypertonic-hyperoncotic solution is transiently able to reduce extravascular lung water index. This reduction was transient but might prevent the triggering of a clinically relevant capillary leakage syndrome. This is in line with in vitro studies demonstrating that hypertonic-hyperoncotic solution improves microcirculation by reducing vascular permeability. The single administration of hypertonic-hyperoncotic solution infusion was safe, and no adverse effects, such as hemostatic disturbances, were observed.

CONCLUSIONS

A single infusion of hypertonic-hyperoncotic saline solution after cardiac surgery is safe despite the hypertonicity and the colloid component of the hypertonic-hyperoncotic saline solution. In children after cardiopulmonary bypass surgery, the administration of hypertonic-hyperoncotic saline solution increased cardiac index by elevating stroke volume index in combination with a lowered systemic vascular resistance index. Extravascular lung water index transiently decreased, suggesting that hypertonic-hyperoncotic saline solution effectively counteracts the capillary leakage that often occurs after cardiac surgery in children. Additional investigations might elucidate whether the temporary effects of hypertonic-hyperoncotic saline solution are beneficial in the treatment of severe capillary leakage after complicated cardiac surgery. It has to be shown that hypertonic-hyperoncotic saline solution is a long-lasting, effective treatment strategy for low cardiac output failure in children that is caused by sepsis, multiorgan failure, and endothelial edema. We have provided evidence to pediatric intensive care clinicians that the single administration of hypertonic-hyperoncotic saline solution might be a useful and safe treatment in the amelioration of contractility, inotropy, and the possible treatment of early-onset capillary leakage.

摘要

目的

高渗 - 高渗胶体溶液用于改善各类休克中的微循环和大循环。在儿科重症医学中,缺乏关于高渗 - 高渗胶体溶液的对照、随机研究。高渗 - 高渗胶体溶液可能改善儿童的心功能。这项对照、随机、双盲研究的主要目的是评估先天性心脏病患儿心脏直视手术后短期内输注高渗 - 高渗胶体溶液的血流动力学效应和安全性。次要目的是确定输注高渗 - 高渗胶体溶液是否可能是预防儿童心脏直视手术后经常发生的可能的毛细血管渗漏综合征的潜在有效治疗选择。

方法

将患儿随机分为两组,每组25例。高渗 - 高渗胶体溶液组接受聚(O - 2) - 羟乙基淀粉60.0 g,分子量为200 kDa,Na⁺ 1232 mmol/L,渗透压为2464 mOsmol/L(7.2%氯化钠与6% 200 kDa羟乙基淀粉)。等渗盐溶液组接受等渗盐溶液(0.9%氯化钠)。使用同种异体移植补片矫正房间隔和室间隔缺损。监测包括动脉导管、中心静脉导管和热稀释导管(PULSIOCATH)。测量心脏指数、血管外肺水指数、每搏量指数、平均动脉血压和全身血管阻力指数(脉搏轮廓心输出量技术)。手术后立即,患者接受高渗 - 高渗胶体溶液或等渗盐溶液负荷(4 mL/kg)。在容量负荷结束前、结束后立即、15分钟后以及1、4、12和24小时采集血样(钠浓度、渗透压、血小板计数、纤维蛋白原和动脉血气)。同时记录血流动力学参数。记录所需多巴酚丁胺的总量以及24小时和48小时的液体平衡情况。

结果

在高渗 - 高渗胶体溶液组中,容量给药前心脏指数为3.6 ± 0.26 L/min·m²,给予研究溶液后增至5.96 ± 0.27(增加64%)。给药后15分钟和60分钟,心脏指数仍显著升高(分别为5.55 ± 0.29 L/min·m²和4.65 ± 0.18 L/min·m²),4小时后恢复至给药前值。在等渗盐溶液组中,整个观察期内心脏指数无变化(等渗盐溶液给药前为3.39 ± 0.21,给药后为3.65 ± 0.23 L/min·m²)。高渗 - 高渗胶体溶液组给药后全身血管阻力指数从1396 ± 112降至868 ± 63 dyn/sec·cm⁻⁵/m²。高渗 - 高渗胶体溶液组全身血管阻力指数的降低在给药后60分钟内短暂显著,但仍低于容量负荷前(999 ± 70 dyn/sec·cm⁻⁵/m²)。在等渗盐溶液组中,全身血管阻力指数无统计学上的相关变化。与给药前的每搏量指数(32.4 ± 2.6 mL/m²)相比,高渗 - 高渗胶体溶液输注后每搏量指数显著增加(给药后立即为53.9 ± 3.0 mL/m²,15分钟后为48.8 ± 2.46 mL/m²,60分钟后为41.4 ± 2.2 mL/m²)。与等渗盐溶液组相比,高渗 - 高渗胶体溶液组给药后60分钟内平均动脉血压的升高短暂显著,等渗盐溶液组中平均动脉血压保持不变。两组在整个观察期间中心静脉压和心率均无变化。在高渗 - 高渗胶体溶液组中,血管外肺水指数从10.6 ± 1.2降至5.6 ± 1.2 mL/kg,与容量给药前相比,15分钟后仍显著降低(6.5 ± 1.2 mL/kg)。在等渗盐溶液组中,给药后血管外肺水指数从12.3 ± 1.1 mL/kg直接增至18.1 ± 1.7 mL/kg,并在容量负荷后60分钟内保持升高(15.6 ± 1.5 mL/kg)。所有患者均未观察到低氧血症(Pa(O₂)<60 mmHg)或高碳酸血症(Pa(CO₂)>60 mmHg)。动脉血气分析显示pH值和碱剩余在生理范围内,且在整个观察期内未发生变化。输注高渗 - 高渗胶体溶液后,钠浓度从139.2 ± 0.7增至147.5 ± 0.7 mmol/L。1例患者在输注高渗 - 高渗胶体溶液后立即测得的最高钠浓度为153 mmol/L。两组输注的液体总量相似。与等渗盐溶液组相比,高渗 - 高渗胶体溶液组患者术后多巴酚丁胺的需求量减少(46.9 ± 8.8 μg/kg vs 308.2 ± 46.6 μg/kg)。无患者出现严重出血。短期和长期心脏及神经结局未降低,所有患者出院时临床状态良好。

讨论

本研究表明,在无并发症的心脏直视手术后儿童中,输注高渗 - 高渗胶体溶液后心脏指数显著增加,提示正性肌力作用。儿茶酚胺总量较低,推测高渗 - 高渗胶体溶液减少了对正性肌力支持的需求。高渗 - 高渗胶体溶液观察到的正性心脏作用甚至可能因后负荷降低(全身血管阻力指数降低)而增强。根据Frank - Starling关系,治疗低心输出量的有效方法是在降低后负荷的同时提高前负荷。因此,我们推测高渗 - 高渗胶体溶液可能有助于预防或减轻儿童低心输出量衰竭。毛细血管渗漏综合征也是体外循环后的常见问题。为了量化水肿形成,血管外肺水指数测量是一种有用的工具。通过这种方法,我们提供了证据表明输注高渗 - 高渗胶体溶液能够短暂降低血管外肺水指数。这种降低是短暂的,但可能预防临床上相关的毛细血管渗漏综合征的触发。这与体外研究结果一致,即高渗 - 高渗胶体溶液通过降低血管通透性改善微循环。单次输注高渗 - 高渗胶体溶液是安全的,未观察到诸如止血障碍等不良反应。

结论

心脏手术后单次输注高渗 - 高渗盐溶液尽管具有高渗性和高渗 - 高渗盐溶液的胶体成分,但仍是安全的。在体外循环手术后的儿童中,输注高渗 - 高渗盐溶液通过提高每搏量指数并降低全身血管阻力指数来增加心脏指数。血管外肺水指数短暂降低,提示高渗 - 高渗盐溶液有效对抗儿童心脏手术后经常发生的毛细血管渗漏。进一步的研究可能阐明高渗 - 高渗盐溶液的暂时作用在治疗复杂心脏手术后严重毛细血管渗漏方面是否有益。必须证明高渗 - 高渗盐溶液是治疗由败血症、多器官功能衰竭和内皮水肿引起的儿童低心输出量衰竭的持久、有效治疗策略。我们已向儿科重症监护临床医生提供证据表明,单次输注高渗 - 高渗盐溶液可能是改善收缩性、变力性以及可能治疗早期毛细血管渗漏的有用且安全的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验